Charlene Beebe, RN | |
505 Mid Ocean Dr, Dagsboro, DE 19939 | |
(302) 537-4024 | |
Not Available |
Full Name | Charlene Beebe |
---|---|
Gender | Female |
Speciality | Registered Nurse |
Location | 505 Mid Ocean Dr, Dagsboro, Delaware |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093170177 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
163W00000X | Registered Nurse | L1-0042102 (Delaware) | Primary |
Mailing Address | Practice Location Address |
---|---|
Charlene Beebe, RN 505 Mid Ocean Dr, Dagsboro, DE 19939-9243 Ph: (302) 537-4024 | Charlene Beebe, RN 505 Mid Ocean Dr, Dagsboro, DE 19939 Ph: (302) 537-4024 |
News Archive
Any patient with a breast lesion classified as a radial scar classified at percutaneous biopsy should undergo a surgical excision to rule out an underlying malignancy, according to a study published in the April issue of the American Journal of Roentgenology (www.ajronline.org).
The measure, termed as "historic" and "controversial" in local media reports, will create the health law's online insurance marketplace. The next planning and implementation steps will now fall to the state's executive branch.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin was submitted to the United States Food and Drug Administration on Wednesday, September 24, 2014.
A new study shows that patients with rheumatic diseases across Africa, Southeast Asia, the Americas and Europe had trouble filling their prescriptions of antimalarial drugs, including hydroxychloroquine, during the 2020 global coronavirus pandemic, when antimalarials were touted as a possible COVID-19 treatment.
BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that analysis of U.S. longitudinal patient-level claims data reveals the use of Bristol-Myers Squibb's oral Abilify as a first-line therapy for newly diagnosed schizophrenia patients continues to grow.
› Verified 1 days ago
Laura Wakeley, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 30934 Vines Creek Rd, Dagsboro, DE 19939 Phone: 609-204-4437 | |
Susan Lynn White, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 32612 Falling Point Rd, Dagsboro, DE 19939 Phone: 443-655-4912 |